Abstract:We investigated associations between inflammatory marker levels and hepatitis C virus (HCV)-related compensated liver cirrhosis risk in patients with chronic hepatitis C (CHC) infection in China. We used a case-control design and data from the records of 110 Chinese patients with CHC and cirrhosis for the study; 458 CHC patients who did not have a diagnosis of cirrhosis were matched to the case group by age and sex characteristics. We also investigated fatty liver disease risk factors. The group of patients with CHC infection and cirrhosis had lower platelet-to-lymphocyte ratio (PLR) values (60.63 [44.09, 89.31]) compared with the control group patients (80.24 [57.85, 111.08]). The results indicated that the group of patients with cirrhosis had higher 4-factor fibrosis index and aspartate aminotransferase (AST)-to-platelet ratio index (APRI) values compared with the group of patients with CHC-only (1.66 [0.98, 2.60] vs 0.71 [0.45, 1.17], respectively; P < .001 and 2.12 [0.97, 4.25] vs 0.99 [0.51, 2.01], respectively; P < .001). Compared with the control group, the AST/alanine aminotransferase ratio (AAR) values in the group of patients with cirrhosis were significantly higher (P < .001). Logistic regression analysis that included model adjustment for demographic characteristics and other factors that could affect cirrhosis risk revealed that greater 1/PLR values were associated with an increased odds of having cirrhosis (adjusted odds ratio [AOR], 95% confidence interval [CI] 0.991 [0.985-0.996]); APRI and AAR values were also independent predictors of the presence of compensated cirrhosis. We found that compared with the patients with CHC-only, the triglyceride, cholesterol, and low-density lipoprotein cholesterol levels in the patients with both CHC and fatty liver disease were significantly higher. The multivariate analysis of the risk of fatty liver development in patients with CHC infection found that cholesterol level was a statistically significant risk factor (AOR [95% CI] 1.380 [1.089-1.750], P = .008). Increased 1/PLR, APRI, and AAR values were associated with increased risks for development of cirrhosis in this population of Chinese patients with CHC infection. Higher cholesterol levels increased the risk of development of fatty liver disease in patients with CHC.

Adiponectin: A Biomarker for Chronic Hepatitis C?

Association Between Adiponectin and Chronic Hepatitis C

Circulating Ectodysplasin A is a Potential Biomarker for Nonalcoholic Fatty Liver Disease.

Adiponectin as a biomarker in liver cirrhosis—A systematic review and meta‐analysis

Adipose tissue regulates hepatic cholesterol metabolism via adiponectin

Critical role of triglycerides for adiponectin levels in hepatitis C: a joint study of human and HCV core transgenic mice

Insulin resistance, serum visfatin, and adiponectin levels are associated with metabolic disorders in chronic hepatitis C virus-infected patients.

[The Role of Apolipoprotein C3 in the Regulation of Nonalcoholic Fatty Liver Disease, Glucose and Lipid Metabolism, and Islet Β Cell Function].

Lipidomic Profiling of Plasma in Patients with Chronic Hepatitis C Infection.

The Role of Adiponectin and Adiponectin Receptor 2 in the Pathology of Fatty Liver

The Relationship Between Adiponectin and Leptin in Cirrhosis

Adiponectin Alleviates Diet-Induced Inflammation in the Liver by Suppressing MCP-1 Expression and Macrophage Infiltration

Apolipoprotein H-based Prognostic Risk Correlates with Liver Lipid Metabolism Disorder in Patients with HBV-related Hepatocellular Carcinoma.

Protective Roles of Adiponectin in Obesity-Related Fatty Liver Diseases: Mechanisms and Therapeutic Implications

Role of Adiponectin in Nonalcoholic Fatty Liver Disease

Adiponectin Modulates C-Jun N-Terminal Kinase and Mammalian Target of Rapamycin and Inhibits Hepatocellular Carcinoma

The Function Role of HIGD1A in Nonalcoholic Steatohepatitis from Chronic Hepatitis B.

Chronic hepatitis C virus infection: Relationships between inflammatory marker levels and compensated liver cirrhosis.

Mechanism of Action and Risk Prediction of Adiponectin in Cardiovascular Diseases

Expression of Adiponectin and Its Receptors in Livers of Morbidly Obese Patients with Non-Alcoholic Fatty Liver Disease.

Variations of Serum Adiponectin and Their Clinical Significance in Liver Cirrhosis